Stocktoria

Pelthos Therapeutics Inc. PTHS

NYSE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-16

Pelthos Therapeutics Inc. statistics & valuation

Market cap$95.8M
P / S5.7×
P / B2.5×
Net margin-257.9%
Return on equity-111.4%
FCF margin-135.1%
Return on capital-31.1%

Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-257.90% 2022202320242025
Gross margin (%)
2022202320242025
Operating margin (%)
-193.10% 2022202320242025
Return on equity (%)
-111.40% 2022202320242025
Shares outstanding
1.1M 3.9M 610389 3.2M 2022202320242025
Net debt ($)
2022202320242025
Share buybacks ($)
2022202320242025
Return on assets (%)
-4464.20% -7657.10% -581.10% -33.20% 2022202320242025
Free cash flow margin (%)
-135.10% 2022202320242025
Debt / equity (×)
2022202320242025
EPS ($)
-$5.78 -$14.27 -$23.04 2022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022
Operating margin-193.1%———
Net margin-257.9%———
FCF margin-135.1%———
Return on assets-33.2%-581.1%-7657.1%-4464.2%
Return on equity-111.4%293.1%114.5%66.3%
Current ratio2.050.340.010.01

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.